<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00730145</url>
  </required_header>
  <id_info>
    <org_study_id>A5361032</org_study_id>
    <nct_id>NCT00730145</nct_id>
  </id_info>
  <brief_title>A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis</brief_title>
  <official_title>A Phase I, Open-Label, Single Dose Study To Evaluate The Pharmacokinetics, Safety, And Tolerability Of PD-0332334 In Subjects Receiving Chronic Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. Quantify how much PD-0332334 is removed from the blood with hemodialysis

        2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving
           regular hemodialysis treatments.

        3. Investigate the safety and tolerability of a single dose of PD-0332334 in subjects
           receiving hemodialysis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Assess the elimination of PD-0332334 from the blood with hemodialysis
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2009</completion_date>
  <primary_completion_date type="Actual">January 2009</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum plasma concentration (Cmax) of PD-0332334 and time of maximum plasma concentration (Tmax). Half-life of PD-0332334 in this patient population with hemodialysis and without hemodialysis</measure>
    <time_frame>0 to 8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Hemodialysis clearance of PD-0332334 from the blood, the total amount and fraction of total dose of PD-0332334 removed from the blood via hemodialysis, and the half-life of drug removal from the blood via hemodialysis</measure>
    <time_frame>0 to 8 days</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the curve (AUC) of PD-0332334 from time of study medication administration to infinity (AUCinf); AUC of PD-0332334 from time of study medication administration to last quantifiable plasma concentration (AUClast).</measure>
    <time_frame>0 to 8 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assess adverse events, findings from physical examinations, clinical safety laboratory assessments, ECG, vital signs.</measure>
    <time_frame>0 to 8 days</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">8</enrollment>
  <condition>Renal Dialysis</condition>
  <condition>Pharmacokinetics</condition>
  <arm_group>
    <arm_group_label>PD-0332334</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PD-0332334</intervention_name>
    <description>A single, 50 mg oral dose (2 capsules) of PD-0332334 will be administered to each hemodialysis subject</description>
    <arm_group_label>PD-0332334</arm_group_label>
    <other_name>imagabalin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients receiving regular hemodialysis

          -  Male or female patients 18 to 65 years

        Exclusion Criteria:

          -  Severe heart failure

          -  Renal transplant or renal allograft

          -  Illicit drug use (with the exception of prescribed sedatives)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <zip>32809</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A5361032&amp;StudyName=A%20Single%20Dose%20Study%20Investigating%20The%20Elimination%20Of%20PD-0332334%20In%20Patients%20Receiving%20Regular%20Hemodialysis</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>February 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 6, 2008</study_first_submitted>
  <study_first_submitted_qc>August 7, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2008</study_first_posted>
  <last_update_submitted>February 16, 2010</last_update_submitted>
  <last_update_submitted_qc>February 16, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 17, 2010</last_update_posted>
  <responsible_party>
    <name_title>Director, Clinical Trial Disclosure Group</name_title>
    <organization>Pfizer, Inc.</organization>
  </responsible_party>
  <keyword>pharmacokinetics, PD-0332334, hemodialysis, renal dialysis</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

